Adam S. Dingens
About
In The Last Decade
Adam S. Dingens
27 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Infectious Diseases 3.2k
- Molecular Biology 1.4k
- Radiology, Nuclear Medicine and Imaging 540
- Animal Science and Zoology 450
- Immunology 437
Countries citing papers authored by Adam S. Dingens
This map shows the geographic impact of Adam S. Dingens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam S. Dingens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam S. Dingens more than expected).
Fields of papers citing papers by Adam S. Dingens
This network shows the impact of papers produced by Adam S. Dingens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam S. Dingens. The network helps show where Adam S. Dingens may publish in the future.
Co-authorship network of co-authors of Adam S. Dingens
This figure shows the co-authorship network connecting the top 25 collaborators of Adam S. Dingens. A scholar is included among the top collaborators of Adam S. Dingens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam S. Dingens. Adam S. Dingens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 17 | |
| 2 | Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 breakdown → | 448 |
| 3 | 14 | |
| 4 | Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 breakdown → | 280 |
| 5 | 152 | |
| 6 | 44 | |
| 7 | Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays breakdown → | 435 |
| 8 | Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding breakdown → | 1130 |
| 9 | Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition breakdown → | 568 |
| 10 | 312 | |
| 11 | 27 | |
| 12 | 53 | |
| 13 | 14 | |
| 14 | 34 | |
| 15 | 75 | |
| 16 | 66 | |
| 17 | 14 | |
| 18 | 54 | |
| 19 | 61 | |
| 20 | 23 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.